Market closedNon-fractional

Catalyst Pharmaceuticals/CPRX

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Ticker

CPRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Coral Gables, United States

Employees

167

CPRX Metrics

BasicAdvanced
$1.9B
Market cap
28.02
P/E ratio
$0.56
EPS
0.89
Beta
-
Dividend rate
$1.9B
0.89
5.085
4.663
0.551
0.551
9.29%
14.55%
28.02
4.19
3.32
4.96
37.81
60.38%
-36.55%
50.72%
-6.04%

What the Analysts think about CPRX

Analyst Ratings

Majority rating from 7 analysts.
Buy

CPRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
23.55% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$99M
-10.86%
Net income
$23M
-33.33%
Profit margin
23.55%
-25.21%

CPRX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.46%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.33
-$0.29
$0.31
$0.19
-
Expected
$0.36
-$0.29
$0.27
$0.17
$0.26
Surprise
-7.30%
1.75%
16.98%
14.46%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals (CPRX) has a market cap of $1.9B as of July 05, 2024.

What is the P/E ratio for Catalyst Pharmaceuticals stock?

The price to earnings (P/E) ratio for Catalyst Pharmaceuticals (CPRX) stock is 28.02 as of July 05, 2024.

Does Catalyst Pharmaceuticals stock pay dividends?

No, Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Catalyst Pharmaceuticals dividend payment date?

Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (CPRX) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Catalyst Pharmaceuticals stock

Buy or sell Catalyst Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing